|
rs3087918
|
TT
|
TG
|
GG
|
TG + GG
|
|---|
|
Age
|
|
> 49/<=49
|
102/69
|
120/87
|
28/19
|
148/106
|
|
OR(95%CI)
|
1.00 (reference)
|
0.93 (0.62–1.408)
|
1.00 (0.52–1.95)
|
0.94 (0.64–1.40)
|
|
P-value
| |
0.742
|
0.993
|
0.777
|
|
BMI (kg/m2)
|
|
> =24/< 24
|
37/134
|
60/147
|
12/35
|
72/182
|
|
OR(95%CI)
|
1.00 (reference)
|
1.48 (0.92–2.37)
|
1.24 (0.59–2.63)
|
1.43 (0.91–2.26)
|
|
P-value
| |
0.104
|
0.571
|
0.120
|
|
Menstrual status
|
|
yes/no
|
114/57
|
128/79
|
29/18
|
157/97
|
|
OR(95%CI)
|
1.00 (reference)
|
0.81 (0.53–1.24)
|
0.81 (0.42–1.59)
|
0.81 (0.54–1.21)
|
|
P-value
| |
0.330
|
0.526
|
0.307
|
|
Tumor size (cm)
|
|
> 2/<=2
|
85/86
|
107/100
|
31/16
|
138/116
|
|
OR(95%CI)
|
1.00 (reference)
|
1.08 (0.72–1.62)
|
1.96 (1.01–3.92)
|
1.20 (0.82–1.73)
|
|
P-value
| |
0.701
|
0.050
|
0.350
|
|
Metastasis
|
|
Positive/negtive
|
93/78
|
104/103
|
24/23
|
128/126
|
|
OR(95%CI)
|
1.00 (reference)
|
0.85 (0.56–1.27)
|
0.88 (0.46–1.68)
|
0.85 (0.58–1.26)
|
|
P-value
| |
0.422
|
0.686
|
0.419
|
|
Clinical Stage
|
|
III-IV/I-II
|
51/120
|
59/148
|
16/31
|
75/179
|
|
OR(95%CI)
|
1.00 (reference)
|
0.94 (0.60–1.47)
|
1.21 (0.60–2.39)
|
0.99 (0.65–1.51)
|
|
P-value
| |
0.778
|
0.579
|
0.948
|
|
ER
|
|
Positive/negtive
|
115/56
|
138/69
|
33/14
|
171/83
|
|
OR(95%CI)
|
1.00 (reference)
|
0.97 (0.63–1.50)
|
1.15 (0.58–2.37)
|
1.00 (0.66–1.51)
|
|
P-value
| |
0.904
|
0.700
|
0.988
|
|
PR
|
|
Positive/negtive
|
94/77
|
112/95
|
33/14
|
145/109
|
|
OR(95%CI)
|
1.00 (reference)
|
0.97 (0.64–1.45)
|
1.93 (0.98–3.97)
|
1.09 (0.74–1.61)
|
|
P-value
| |
0.867
|
0.063
|
0.666
|
|
Her-2
|
|
Positive/negtive
|
62/109
|
90/117
|
27/20
|
117/137
|
|
OR(95%CI)
|
1.00 (reference)
|
1.35 (0.89–2.05)
|
2.37 (1.24–4.63)
|
1.50 (1.01–2.24)
|
|
P-value
| |
0.155
|
0.01*
|
0.045*
|
- BMI: body mass index, ER: estrogen receptor, PR: progesterone receptor, Her-2: human epidermal growth factor receptor-2, OR: odds ratio, CI: confidence interval
- *The P Value < 0.05
